gila monster glp 1 The GLP-1 Story... (a GoggleDocs Podcast) Gila Monster Venom: The Unexpected

Several studies have relatively short follow-up periods and limited sample sizes, which may constrain the evaluation of long-term efficacy and durability

These statements have not been evaluated by the Food and Drug Administration (FDA)

Multiple cost-reduction methods can address these financial barriers effectively

More data are needed to clarify the effects of GLP-1RAs on the incidence of OA, RA, PsA and axSpA, as well as on disease activity and progression in these conditions

Adverse reactions were compared between combination therapy and monotherapy (GLP-1 RAs or metformin alone), followed by stratified analyses by gender, age, and body weight

Weight loss is linked to reduced hepatic steatosis